

RETRACTION NOTE

Open Access



# Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Faiza Naseer<sup>1,2\*</sup>, Kousain Kousar<sup>1</sup>, Maisa S. Abduh<sup>3</sup>, Sadia Anjum<sup>4</sup> and Tahir Ahmad<sup>1\*</sup>

The original article can be found online at <https://doi.org/10.1186/s12645-023-00218-2>.

\*Correspondence:  
faiza.naseer@gmail.com;  
tahir@asab.nust.edu.pk

<sup>1</sup> Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan

<sup>2</sup> Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan

<sup>3</sup> Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589 Jeddah, Saudi Arabia

<sup>4</sup> Department of Biology, University of Hail, Hail, Saudi Arabia

**Retraction Note: *Cancer Nanotechnology* (2023) 14:65**

<https://doi.org/10.1186/s12645-023-00218-2>

The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:

- Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)
- Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar
- Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)
- Fig. 18 C6 and D6 appear to overlap (with different magnification)
- Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)

The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.

None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.



©The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Published online: 27 July 2024

#### References

- Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. *Int J Nanomed* 18:185–205. <https://doi.org/10.2147/IJN.S386560>
- Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. *Cancer Nano* 14:71. <https://doi.org/10.1186/s12645-023-00220-8>

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.